片頭痛の疫学予測(~2026年)

◆英語タイトル:EpiCast Report: Migraine - Epidemiology Forecast to 2026
◆商品コード:GDHCER158-17
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年8月10日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥451,435見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥902,870見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,354,305見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

EpiCast Report: Migraine – Epidemiology Forecast to 2026
Summary

Migraine is characterized by recurring headaches and throbbing pain on one side of the head accompanied by nausea, vomiting, or increased sensitivity to light or smell. While most migraineurs experience episodic migraines (EM), a small percentage suffers from chronic migraine (CM). In addition to its debilitating pain, migraines are also associated with more severe cardiovascular and neuropsychological comorbidities. Because migraine is one of the most prevalent types of headache, there is a substantial economic and social burden associated with the condition worldwide, and it is therefore recognized as a high-priority public health problem by the World Health Organization.

In 2016, there were 73,914,635 total prevalent cases of migraine in adults ages 18 years and older in the 7MM. The US had the most cases, while Spain had the fewest. In the 7MM, the number of total prevalent cases of migraine is expected to grow to 74,543,569 by 2026, at an Annual Growth Rate (AGR) of 0.09%. Since age- and sex-specific prevalence was held constant throughout the forecast period, all changes in the total prevalent cases of migraine are the result of demographic changes. GlobalData epidemiologists estimate that 1.61% of total migraine cases in the 7MM in 2016 were CM.

This forecast is supported by country-specific prevalence studies for each market, most of which are based on nationally representative samples. GlobalData epidemiologists are confident that these sources provide the most accurate and robust data available in each market. Additionally, GlobalData epidemiologists used consistent methodology while creating forecasts for each market. This allows useful and accurate comparisons regarding total prevalent cases of migraine between markets.

Scope

- The Migraine EpiCast Report provides an overview of the risk factors and global trends of migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of migraine segmented by sex and age (for ages 18 years and older) in these markets. This forecast is further segmented by migraine frequency into episodic migraine (EM) and chronic migraine (CM).
- The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Migraine EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global migraine market.
- Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for migraine therapeutics in each of the markets covered.
- Identify the percentage of migraine prevalent cases by frequency.

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Related Reports 5
2.2 Upcoming Reports 5
3 Epidemiology 6
3.1 Disease Background 6
3.2 Risk Factors and Comorbidities 6
3.3 Global and Historical Trends 9
3.3.1 US 10
3.3.2 5EU 11
3.3.3 Japan 11
3.4 Forecast Methodology 11
3.4.1 Sources 12
3.4.2 Forecast Assumptions and Methods 14
3.5 Epidemiological Forecast for Migraine (2016-2026) 17
3.5.1 Total Prevalent Cases of Migraine 17
3.5.2 Age-Specific Total Prevalent Cases of Migraine 18
3.5.3 Sex-Specific Total Prevalent Cases of Migraine 19
3.5.4 Migraine Cases by Frequency of Occurrences 20
3.6 Discussion 21
3.6.1 Epidemiological Forecast Insight 21
3.6.2 Limitations of Analysis 22
3.6.3 Strengths of Analysis 23
4 Appendix 24
4.1 Bibliography 24
4.2 About the Authors 28
4.2.1 Epidemiologist 28
4.2.2 Reviewers 28
4.2.3 Global Director of Therapy Analysis and Epidemiology 29
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 29
4.3 About GlobalData 30
4.4 Contact Us 30
4.5 Disclaimer 30

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Migraine 8
Table 2: ICHD-3 Diagnostic Criteria for Migraine 12
Table 3: Total Prevalent Cases of Migraine, Ages ≥18 Years, Both Sexes, N, Select Years 2016-2026 18

1.2 List of Figures
Figure 1: 7MM, Total Prevalent Cases of Migraine, Both Sexes, Ages ≥18 Years, 2016 and 2026 5
Figure 2: 7MM, Age-Standardized Total Prevalence of Migraine, Both Sexes, Ages ≥18 Years, 2016 10
Figure 3: Sources Used and Not Used in Epidemiological Analysis of Migraine Prevalence 13
Figure 4: Sources Used and Not Used in Epidemiological Analysis of Migraine Frequency 14
Figure 5: 7MM, Age-Specific Total Prevalent Cases of Migraine, Both Sexes, Ages ≥18 Years, 2016 19
Figure 6: 7MM, Sex-Specific Total Prevalent Cases of Migraine, Ages ≥18 Years, 2016 20
Figure 7: 7MM, Total Prevalent Migraine Cases by Frequency of Occurrences, Both Sexes, Ages ≥18 Years, 2016 21

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[片頭痛の疫学予測(~2026年)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆